Abstract:

Objective   To explore the relationship between CD36 single nucleotide polymorphisms and atherosclerotic cerebral infarction in elderly patients. Methods   121 patients with atherosclerotic cerebral infarction who were older than 75 years were enrolled into the case group.217 health-examination people who had no cerebral infarction were selected as the control group. PCR-LDR was used to detect the genotype of rs1761667 and rs9784998 which are two locis of CD36. Enzyme linked immunosorbent assay (ELISA) was used for determination of plasma thromboxane B2. Results   There were no significant differences in genotype and allele frequencies of rs9784998 between case and control groups(P＞0.05). AG genotype frequency distribution of rs1761667 between the two groups had significant difference (χ2=7.03, P＜0.01). Logistic multifactor analysis and stepwise regression analysis showed that, compared to the other two genotypes, AG genotype could increase the risk of cerebral infarction(P＜0.05). The levels of plasma thromboxane B2 in case group was significantly higher than in control group(P＜0.01), but the thromboxane B2 in patients with AG genotype had no statistical difference between the two groups(P＞0.05). Conclusion   rs9784998 is not statistically associated with atherosclerotic cerebral infarction. rs1761667 is a genetic risk factor of atherosclerotic cerebral infarction. CD36 SNPs have no statistical correlation with plasma thromboxane B2.

Key words: Atherosclerotic cerebral infarction; CD36; Single nucleotide polymorphism; Thromboxane B2